|
Patent landscape, scope, and claims: |
U.S. Patent 8,663,685: Scope, Claims, and Patent Landscape Analysis
What does U.S. Patent 8,663,685 Cover?
U.S. Patent 8,663,685, titled "Methods of Treating Disease Using Small Molecules," was granted on March 4, 2014. It covers novel small-molecule compounds and methods for treating specific diseases, predominantly focused on kinase inhibition for cancer therapy. The patent claims include compound compositions, their synthesis, and methods of use for treating cancer and related diseases.
Patent Scope
The patent encompasses:
- A class of small-molecule compounds characterized by particular chemical structures.
- Synthesis routes for these compounds.
- Methods for administering the compounds to treat disorders such as cancer, inflammatory diseases, or disorders involving abnormal cell proliferation.
- Specific chemical substitutions and structural modifications that optimize activity.
The patent's scope is considerable, as it claims a broad class of compounds with variations on core heterocyclic structures, including substitutions that enhance kinase inhibition.
What Are the Key Claims?
The claims primarily define:
- Compound claims: Chemical structures formulated as formulas (e.g., Formula I) with variable groups identified as R1, R2, etc. For example, claims specify structures where R1 and R2 can be hydrogen, halogens, or alkyl groups, subject to certain constraints.
- Use claims: Methods of using the compounds to inhibit kinases in vitro and in vivo, and methods for treating cancer, such as non-small cell lung carcinoma or breast cancer.
- Manufacturing claims: Processes for synthesizing the compounds using specific chemical reactions.
- Dosage and administration claims: Although not explicitly detailed, claims include methods of delivering therapeutically effective doses over prescribed treatment regimes.
Sample of the Claim Structure
Claims 1, 10, and 20 illustrate the breadth:
- Claim 1 describes a compound with a heterocyclic core and specific substituents, with broad variations.
- Claim 10 narrows the scope to specific subclasses of compounds.
- Claim 20 addresses methods of treatment using the claimed compounds.
Patent Landscape: Similar and Related Patents
Key Related Patents and Patent Families
- International Patent Family: The patent family includes counterparts filed in Europe (EP 2,500,789), Japan, China, and other jurisdictions, indicating broad geographical coverage.
- Competitor Patents: Several entities, including pharmaceutical companies and biotech firms, hold patents on kinase inhibitors targeting similar cancer pathways (e.g., EGFR inhibitors, ALK inhibitors).
- Patent Clusters: Several overlapping patents cover heterocyclic cores resembling those in 8,663,685, illustrating targeted patenting strategies for kinase inhibitors.
Patent Position in the Landscape
- The patent sits within a dense area of kinase inhibitor patents.
- The claims may face challenge or design-around opportunities due to overlapping patents from competitors.
- The broad structural claims provide a wide foothold but may be limited by prior art regarding specific heterocyclic modifications.
Critical Analysis of Limitations and Potential Challenges
- Prior Art Concerns: Earlier patents in kinase inhibitors, including those from Pfizer, Novartis, and other pharmaceutical companies, disclose similar core structures, possibly limiting claim enforceability.
- Claim Breadth vs. Specificity: Broad claims risk invalidation or restriction based on prior art, whereas narrower claims could limit commercial scope.
- Patent Term and Expiry: Filed in 2011 and granted in 2014, the patent's expiration date extends to 2031 (considering patent term adjustment), affecting market exclusivity.
Implications for R&D and Commercial Strategy
- The broad compound claims enable developing multiple derivatives within the scope.
- Use claims reinforce methods of treatment, protecting the therapeutic application.
- Patent family coverage supports global rights, enabling international market entry.
Key Takeaways
- U.S. Patent 8,663,685 claims a broad class of kinase inhibitor compounds with therapeutic applications in oncology.
- The claims cover chemical structures, synthesis methods, and treatment methods, offering comprehensive patent protection.
- The patent landscape is crowded, with overlapping patents in kinase inhibition, challenging the scope's robustness.
- Strategic patent positioning should focus on specific compound derivatives or combination therapies to avoid infringement.
- The patent's expiration in 2031 provides a window for commercialization and further innovation.
FAQs
Q1: Are the claims of U.S. Patent 8,663,685 still enforceable?
Yes, provided they have not been challenged successfully or invalidated, the patent remains enforceable until 2031.
Q2: What type of diseases can be targeted with the compounds claimed in this patent?
Primarily cancers such as non-small cell lung carcinoma and breast cancer, but also other kinase-related diseases.
Q3: How broad are the chemical scope claims?
They cover a wide range of heterocyclic compounds with various substitutions, offering significant breadth but subject to prior art limitations.
Q4: How does this patent relate to existing kinase inhibitors?
It shares structural similarities with other kinase inhibitors but claims specific modifications intended to improve selectivity and efficacy.
Q5: Are there ongoing legal challenges or litigation related to this patent?
No publicly available information indicates material legal disputes. However, infringement risk depends on specific compound structures and existing patent claims by competitors.
References
- United States Patent and Trademark Office. (2014). U.S. Patent 8,663,685. Retrieved from USPTO.gov.
- WIPO. (n.d.). Global Patent Database. Retrieved from patent documentation.
- European Patent Office. (n.d.). Patent EP 2,500,789. Retrieved from Espacenet.
- Novartis AG. (2010). Patent portfolio on kinase inhibitors. [Patent filings].
More… ↓
⤷ Start Trial
|
